Aggregation of alpha-synuclein into inclusion bodies, termed Lewy pathology, is a defining
feature of Parkinson's disease (PD) and Dementia with Lewy bodies (DLB). In the majority of …

Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …

Importance Novel plasma biomarkers, especially phosphorylated tau (p-tau), can detect
brain tau aggregates in Alzheimer disease. Objective To determine which plasma biomarker …

Down syndrome (DS, trisomy 21) is characterized by intellectual impairment at birth and
Alzheimer's disease (AD) pathology in middle age. As individuals with DS age, their …

INTRODUCTION Almost all individuals with Down syndrome (DS) will develop
neuropathological features of Alzheimer's disease (AD). Understanding AD biomarker …

Background Increasing evidence supports the association between body mass index (BMI),
Alzheimer's disease, and vascular markers. Recently, metabolically unhealthy conditions …

Background: Virtually all adults with Down syndrome (DS) develop Alzheimer's disease (AD)
pathology, but research gaps remain in understanding early signs of AD in DS. Objective …

Background Important insights into the early pathogenesis of Alzheimer's disease can be
provided by studies of autosomal dominant Alzheimer's disease and Down syndrome …

Summary Background Adults with Down syndrome are at risk for Alzheimer's disease.
Natural history cohort studies have characterised the progression of Alzheimer's disease …

Down syndrome (DS) is the most prevalent genetic cause of intellectual disability, resulting
from trisomy 21. Recently, positron emission tomography (PET) imaging has been used to …